The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase 1 positron emission tomography (PET) study of the receptor occupancy of rolapitant, a novel NK-1 receptor antagonist.
Allen Poma
Employment or Leadership Position - Tesaro
Stock Ownership - Tesaro
Jennifer Christensen
Employment or Leadership Position - Tesaro
Stock Ownership - Tesaro
Jennifer Davis
Employment or Leadership Position - Tesaro
Stock Ownership - Tesaro
Vikram Kansra
Employment or Leadership Position - Tesaro
Stock Ownership - Tesaro
Robert E. Martell
Employment or Leadership Position - Tesaro
Stock Ownership - Tesaro
Mary Lynne Hedley
Employment or Leadership Position - Tesaro
Stock Ownership - Tesaro